Patents by Inventor Tamie J Chilcote

Tamie J Chilcote has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240254211
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: January 30, 2024
    Publication date: August 1, 2024
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
  • Publication number: 20210032318
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: April 7, 2020
    Publication date: February 4, 2021
    Applicants: Prothena Biosciences Limited, The Regents of the University of California
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
  • Publication number: 20190300598
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: February 21, 2019
    Publication date: October 3, 2019
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: DALE B. SCHENK, ELIEZER MASLIAH, MANUEL J. BUTTINI, TAMIE J. CHILCOTE, EDWARD M. ROCKENSTEIN, KATE DORA GAMES
  • Publication number: 20180355028
    Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.
    Type: Application
    Filed: May 16, 2018
    Publication date: December 13, 2018
    Inventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
  • Patent number: 9879071
    Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: January 30, 2018
    Assignee: Prothena Biosciences Limited
    Inventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
  • Publication number: 20170349651
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: May 30, 2017
    Publication date: December 7, 2017
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
  • Publication number: 20170204173
    Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 20, 2017
    Inventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
  • Patent number: 9034337
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: May 19, 2015
    Assignee: Prothena Biosciences Limited
    Inventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
  • Patent number: 8506959
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: August 13, 2013
    Assignees: Neotope Biosciences Limited, The Regents of the University of California
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
  • Publication number: 20130072663
    Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.
    Type: Application
    Filed: September 5, 2012
    Publication date: March 21, 2013
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
  • Publication number: 20120201842
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 9, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, ELAN PHARMACEUTICALS, INC.
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
  • Patent number: 8148089
    Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: April 3, 2012
    Assignee: Elan Pharma International Limited
    Inventors: John P. Anderson, Kelly Banducci, Guriqbal S. Basi, David Chereau, Tamie J. Chilcote, Normand L. Frigon, Jr., Jason Goldstein, Irene Griswold
  • Patent number: 8147833
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: April 3, 2012
    Assignees: Neotope Biosciences Limited, The Regents of the University of California
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
  • Patent number: 8092801
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: February 25, 2008
    Date of Patent: January 10, 2012
    Assignee: Neotope Biosciences Limited
    Inventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
  • Publication number: 20110207796
    Abstract: Agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient are provided. Preferred agents include inhibitors of PLK2 kinase.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 25, 2011
    Inventors: John P. Anderson, Kelly Banducci, Guriqbal S. Basi, David Chereau, Tamie J. Chilcote, Normand L. Frigon, JR., Jason Goldstein, Irene Griswold-Prenner
  • Patent number: 7919088
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: April 5, 2011
    Assignees: Elan Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Dale B. Schenk, Kate Dora Games, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Eliezar Masliah
  • Publication number: 20100278814
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: February 25, 2008
    Publication date: November 4, 2010
    Applicants: ELAN PHARMACEUTICALS, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
  • Publication number: 20100143946
    Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.
    Type: Application
    Filed: February 8, 2010
    Publication date: June 10, 2010
    Applicant: ELAN PHARMA INTERNATIONAL LIMITED
    Inventors: JOHN P. ANDERSON, KELLY BANDUCCI, GURIQBAL S. BASI, DAVID CHEREAU, TAMIE J. CHILCOTE, NORMAND L. FRIGON, JR., JASON GOLDSTEIN, IRENE GRISWOLD-PRENNER
  • Publication number: 20100031377
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: August 9, 2005
    Publication date: February 4, 2010
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: Dale B Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
  • Publication number: 20090208487
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: February 23, 2007
    Publication date: August 20, 2009
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Dale B. Schenk, Kate Dora Games, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Eliezar Masliah